Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ADORA3 Biologics Sequence Review Report 2026: Adenosine receptor A3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADORA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADORA2A Biologics Sequence Review Report 2026: Adenosine receptor A2a Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADORA2A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADORA1 Biologics Sequence Review Report 2026: Adenosine receptor A1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADORA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADIPOR1 Biologics Sequence Review Report 2026: Adiponectin receptor protein 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADIPOR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADIPOR2 Biologics Sequence Review Report 2026: Adiponectin receptor protein 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADIPOR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADISSP Biologics Sequence Review Report 2026: Adipose-secreted signaling protein Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADISSP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADCYAP1R1 Biologics Sequence Review Report 2026: Pituitary adenylate cyclase-activating polypeptide type I receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADCYAP1R1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
A1CF Biologics Sequence Review Report 2026: APOBEC1 complementation factor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of A1CF protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SEMA6D Biologics Sequence Review Report 2026: Semaphorin-6D Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of SEMA6D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ACVRL1 Biologics Sequence Review Report 2026: Activin receptor type-1-like Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ACVRL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ACVR1C Biologics Sequence Review Report 2026: Activin receptor type-1C Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ACVR1C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SEMA5A Biologics Sequence Review Report 2026: Semaphorin-5A Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of SEMA5A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.